Solid Biosciences Inc. Net Fee Amt
Solid Biosciences Inc. (SLDB) had Net Fee Amt of $0 as of 2026-08-04, per its S-3ASR filed 2026-08-06.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-08-06
- 2026-08-04: Net Fee Amt $0.00.
| Period end | Net Fee Amt |
|---|---|
| 2026-08-04 | $0.00 S-3ASR · filed 2026-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |